Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Nanna Nyholm, Anne Danø, Henrik Schnack & Giorgio Lorenzo Colombo. (2023) The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis. ClinicoEconomics and Outcomes Research 15, pages 607-619.
Read now
Read now
Nanna Nyholm, Henrik Schnack, Anne Danø & François Skowron. (2023) Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany. Current Medical Research and Opinion 39:6, pages 833-842.
Read now
Read now
Articles from other publishers (2)
Jaroslav Duda. (2022) Cost-effectiveness analysis of biological drugs in treating moderate to severe plaque psoriasis from the perspective of a health service provider. Klinická farmakologie a farmacie 36:2, pages 54-67.
Crossref
Crossref
V. D. Sokolova, N. A. Sableva, V. V. Mladov & D. G. Tolkacheva. (2022) Efficacy of targeted drugs for the treatment of adults with moderate-to-severe plaque psoriasis in the Russian Federation: a systematic literature review update. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 15:1, pages 131-144.
Crossref
Crossref